Insider Selling: Heartflow (NASDAQ:HTFL) Insider Sells $1,595,596.97 in Stock

Heartflow, Inc. (NASDAQ:HTFL) insider Campbell Rogers sold 65,153 shares of Heartflow stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $24.49, for a total transaction of $1,595,596.97. Following the sale, the insider owned 76,034 shares of the company’s stock, valued at approximately $1,862,072.66. This represents a 46.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Heartflow Stock Performance

Shares of HTFL stock opened at $23.99 on Friday. The firm has a market cap of $2.04 billion and a price-to-earnings ratio of -13.25. The business has a 50 day moving average of $29.56. Heartflow, Inc. has a one year low of $20.13 and a one year high of $41.22.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in HTFL. Invesco Ltd. increased its position in shares of Heartflow by 463.9% in the 4th quarter. Invesco Ltd. now owns 577,397 shares of the company’s stock valued at $16,831,000 after purchasing an additional 475,004 shares during the last quarter. XTX Topco Ltd grew its stake in shares of Heartflow by 282.6% during the fourth quarter. XTX Topco Ltd now owns 43,205 shares of the company’s stock worth $1,259,000 after purchasing an additional 31,913 shares in the last quarter. VARCOV Co. purchased a new position in Heartflow in the fourth quarter valued at $1,657,000. Wellington Management Group LLP raised its stake in Heartflow by 20.8% in the fourth quarter. Wellington Management Group LLP now owns 5,894,070 shares of the company’s stock valued at $171,812,000 after buying an additional 1,014,006 shares in the last quarter. Finally, Catalio Capital Management LP purchased a new stake in Heartflow during the 4th quarter worth about $3,319,000.

Wall Street Analyst Weigh In

Several research firms recently issued reports on HTFL. JPMorgan Chase & Co. boosted their price objective on Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Canaccord Genuity Group lifted their target price on Heartflow from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Weiss Ratings reissued a “sell (d)” rating on shares of Heartflow in a research report on Monday, December 29th. Wells Fargo & Company initiated coverage on shares of Heartflow in a report on Wednesday, January 28th. They issued an “overweight” rating and a $38.00 price objective for the company. Finally, Stifel Nicolaus upped their target price on shares of Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.50.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.